Paul Nathan
Professor MB.BS., BA, BSc (hons), PhD, FRCP
Consultant Medical Oncologist
Mount Vernon Cancer Centre, UK
Honorary Professor of Oncology University College London, UK
Honorary Consultant Medical Oncologist University College London Hospitals,UK
After a BSc in Biological Sciences and a PhD in tumour immunology at the University of Birmingham UK, Paul received a Fulbright travel award and went to Pittsburgh Cancer Institute USA as a post-doctoral researcher.
He then returned to the UK initially as a post-doc and then tumour immunology head of laboratory at ICI Pharmaceuticals (later to be Astra Zeneca). Paul then decided to obtain a medical training and after studies at Cambridge University and University College London completed his training in London and was appointed as Consultant Medical Oncologist at Mount Vernon Cancer Centre in 2003.
He has a specialist interest in Melanoma and Renal Cell Carcinoma and has led practice changing studies in both diseases. He is systemic treatment lead for the EORTC Melanoma group. More recently he has led initiatives in uveal melanoma and is Chief Investigator for the current international phase III study adjuvant tebentafusp study.
He established and chairs the UK guideline group on Uveal Melanoma. He is ex-chair of the NCRI Bladder and Renal Carcinoma Clinical Studies Group. He was trustee of Melanoma Focus and Kidney Cancer UK.
He has authored over 150 papers many of which are in the world’s leading journals. He is chief investigator, steering committee and data monitoring committee chair/member for many melanoma and renal carcinoma clinical studies.
He is a contributor to ESMO and EADO guidelines for cutaneous melanoma, uveal melanoma and merkel cell carcinoma. He advises a number of pharmaceutical companies and has given expert testimony to the EMA, MHRA and NICE and NHSE.
He is a member of the scientific evaluation committee for the French National Cancer Institute reference network for rare adult cancers.
Paul was appointed Professor of Medical Oncology at University College London in 2024.
